Dr. Xiaoxia Li, MSc, MD, PhD, DABT

Dr. Xiaoxia Li joined WuXi AppTec in 2020, bringing more than 17 years of preclinical drug development experience to her role and providing clients with quick, efficient scientific and technical support. Dr. Li is an expert in nonclinical drug development including designing/conducting various toxicology programs, performing toxicokinetics modeling, and in silico mutagenicity prediction. Previously, Dr. Li was a scientific leader in nonclinical development for a pharmaceutical company in Toronto, Canada, before starting her own consulting firm, Sunrise Innovative Drug Development (IDD). Dr. Li began her career at Bozo (Biology and Zoology) Research Center, a preclinical Contract Research Organization (CRO) in Tokyo, Japan, and later spent more than 13 years as a study director/ principal toxicologist at ITR Laboratories in Montreal, Canada. Dr. Li earned an MD from Heilongjiang University of Chinese Medicine, MSc from Liaoning University of Traditional Chinese Medicine, and PhD in Pharmacology from Tokyo Medical University in Japan. She is also a Diplomate of the American Board of Toxicology (DABT).